Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTCy for GVHD Prophylaxis in Higher-Risk MDS and AML
NCT06098313Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Jul 2020
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Asan Medical Center. Started Jul 2020; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06098313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098313.